MD3500306T2 - Combinație triplă de agonist invers al receptorului histaminic 3, inhibitor al acetilcolinesterazei și antagonist al receptorului NMDA - Google Patents
Combinație triplă de agonist invers al receptorului histaminic 3, inhibitor al acetilcolinesterazei și antagonist al receptorului NMDAInfo
- Publication number
- MD3500306T2 MD3500306T2 MDE20190713T MDE20190713T MD3500306T2 MD 3500306 T2 MD3500306 T2 MD 3500306T2 MD E20190713 T MDE20190713 T MD E20190713T MD E20190713 T MDE20190713 T MD E20190713T MD 3500306 T2 MD3500306 T2 MD 3500306T2
- Authority
- MD
- Moldova
- Prior art keywords
- histamine
- receptor antagonist
- acetylcholinesterase inhibitors
- nmda
- inverse agonists
- Prior art date
Links
- 229940099433 NMDA receptor antagonist Drugs 0.000 title abstract 5
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title abstract 5
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 4
- 239000002469 receptor inverse agonist Substances 0.000 title 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 239000000018 receptor agonist Substances 0.000 abstract 2
- 229940044601 receptor agonist Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 229960001340 histamine Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Prezenta invenţie se referă la agonişti inverşi ai receptorului histaminei 3 (H3R) sau la sărurile lor acceptabile farmaceutic în combinaţie cu sau pe lângă inhibitori ai acetilcolinesterazei (AChEI) şi antagonistul receptorului N-Metil-D-aspartat (NMDA). De asemenea, prezenta invenţie furnizează un agonist invers al receptorilor de histamină-3 (H3R) sau a celor 10 săruri acceptabile farmaceutic ale acestora în combinaţie cu sau ca adjuvant la inhibitorul acetilcolinesterazei şi antagonistul receptorului N-metil-D-aspartatului (NMDA) şi a acestora utilizare în tratamentul tulburărilor cognitive. Prezenta invenţie furnizează în plus compoziţia farmaceutică care conţine combinaţia menţionată.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641028165 | 2016-08-18 | ||
| PCT/IB2017/054939 WO2018033848A1 (en) | 2016-08-18 | 2017-08-14 | Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3500306T2 true MD3500306T2 (ro) | 2020-10-31 |
Family
ID=59829422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20190713T MD3500306T2 (ro) | 2016-08-18 | 2017-08-14 | Combinație triplă de agonist invers al receptorului histaminic 3, inhibitor al acetilcolinesterazei și antagonist al receptorului NMDA |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20190336509A1 (ro) |
| EP (1) | EP3500306B1 (ro) |
| JP (1) | JP6734469B2 (ro) |
| KR (1) | KR102040639B1 (ro) |
| CN (1) | CN109562180B (ro) |
| AU (1) | AU2017311666B2 (ro) |
| BR (1) | BR112019002637A2 (ro) |
| CA (1) | CA3033050C (ro) |
| CY (1) | CY1123522T1 (ro) |
| DK (1) | DK3500306T3 (ro) |
| EA (1) | EA036480B1 (ro) |
| ES (1) | ES2818898T3 (ro) |
| HR (1) | HRP20201511T1 (ro) |
| HU (1) | HUE051474T2 (ro) |
| IL (1) | IL264405B (ro) |
| LT (1) | LT3500306T (ro) |
| MA (1) | MA45988B1 (ro) |
| MD (1) | MD3500306T2 (ro) |
| MX (1) | MX2019001698A (ro) |
| PL (1) | PL3500306T3 (ro) |
| PT (1) | PT3500306T (ro) |
| RS (1) | RS60832B1 (ro) |
| SG (1) | SG11201900680PA (ro) |
| SI (1) | SI3500306T1 (ro) |
| WO (1) | WO2018033848A1 (ro) |
| ZA (1) | ZA201900436B (ro) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020012912A (es) * | 2018-05-31 | 2021-05-27 | Suven Life Sciences Ltd | Método de tratamiento con el agonista inverso del receptor de histamina-3. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2694492T3 (en) * | 2011-02-23 | 2015-11-09 | Suven Life Sciences Ltd | NOVEL COMPOUNDS AS HISTAMINE H3 receptor ligands |
| FR2974729B1 (fr) * | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
-
2017
- 2017-08-14 MD MDE20190713T patent/MD3500306T2/ro unknown
- 2017-08-14 EA EA201990481A patent/EA036480B1/ru unknown
- 2017-08-14 SI SI201730420T patent/SI3500306T1/sl unknown
- 2017-08-14 BR BR112019002637A patent/BR112019002637A2/pt active Search and Examination
- 2017-08-14 MX MX2019001698A patent/MX2019001698A/es active IP Right Grant
- 2017-08-14 HU HUE17764658A patent/HUE051474T2/hu unknown
- 2017-08-14 CN CN201780048908.1A patent/CN109562180B/zh active Active
- 2017-08-14 CA CA3033050A patent/CA3033050C/en active Active
- 2017-08-14 LT LTEP17764658.5T patent/LT3500306T/lt unknown
- 2017-08-14 PL PL17764658T patent/PL3500306T3/pl unknown
- 2017-08-14 PT PT177646585T patent/PT3500306T/pt unknown
- 2017-08-14 MA MA45988A patent/MA45988B1/fr unknown
- 2017-08-14 KR KR1020197007052A patent/KR102040639B1/ko active IP Right Grant
- 2017-08-14 EP EP17764658.5A patent/EP3500306B1/en active Active
- 2017-08-14 JP JP2019506623A patent/JP6734469B2/ja not_active Expired - Fee Related
- 2017-08-14 WO PCT/IB2017/054939 patent/WO2018033848A1/en unknown
- 2017-08-14 ES ES17764658T patent/ES2818898T3/es active Active
- 2017-08-14 SG SG11201900680PA patent/SG11201900680PA/en unknown
- 2017-08-14 DK DK17764658.5T patent/DK3500306T3/da active
- 2017-08-14 AU AU2017311666A patent/AU2017311666B2/en not_active Ceased
- 2017-08-14 RS RS20201135A patent/RS60832B1/sr unknown
- 2017-08-14 US US16/319,668 patent/US20190336509A1/en not_active Abandoned
-
2019
- 2019-01-22 IL IL264405A patent/IL264405B/en active IP Right Grant
- 2019-01-22 ZA ZA2019/00436A patent/ZA201900436B/en unknown
-
2020
- 2020-09-21 HR HRP20201511TT patent/HRP20201511T1/hr unknown
- 2020-09-22 CY CY20201100891T patent/CY1123522T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013014A (es) | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. | |
| GEP20237506B (en) | Pcsk9 antagonist compounds | |
| DK2345653T3 (da) | Morphinanforbindelser | |
| SG10201902137PA (en) | Cenicriviroc combination therapy for the treatment of fibrosis | |
| TN2017000374A1 (en) | TGF-β INHIBITORS | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| PH12015501754A1 (en) | Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1h)-one derivatives having both �2 adrenergic receptor agonist and m3 muscarinic receptor antagonist activities | |
| MX2016016528A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| MD3288940T2 (ro) | Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA | |
| PH12019502330A1 (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
| MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
| MD3484467T2 (ro) | Combinație de antagoniști ai receptorilor 5-HT6 puri cu inhibitori ai acetilcolinesterazei | |
| MD3458039T2 (ro) | Combinație triplă de antagoniști ai receptorilor 5-HT6 puri, inhibitori ai acetilcolinesterazei și antagonistul receptorului NMDA | |
| MD3500306T2 (ro) | Combinație triplă de agonist invers al receptorului histaminic 3, inhibitor al acetilcolinesterazei și antagonist al receptorului NMDA | |
| MD3500253T2 (ro) | Combinație de agoniști inverşi ai receptorului histaminic 3 cu inhibitori ai acetilcolinesterazei | |
| MD3331873T2 (ro) | Compuși 4-(3-pirazolilamino)-benzimidazol și utilizarea acestora în calitate de inhibitori ai JAK1 | |
| TN2017000248A1 (en) | Cgrp antagonist peptides | |
| MX2014014813A (es) | Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño. |